Deferasirox

Generic Name: Deferasirox

Brand Names: Exjade, Jadenu, 恩瑞格, Deferasirox Accord, Deferasirox Mylan

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₅N_₃O_₄

CAS Number: 201530-41-8

Unique Ingredient Identifier: V8G4MOF2V9

Background: Deferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.

Indication: For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

Associated Conditions: Chronic Iron Overload

Associated Therapies: -

Clinical Trials

Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload

Phase 4

Completed

Conditions: Myelodysplastic Syndromes
Beta-Thalassemia

Interventions: Drug: deferasirox

First Posted Date: 2007-11-29

Last Posted Date: 2017-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 309

Registration Number: NCT00564941

Locations: 🇭🇺
Novartis Investigative Site, Szeged, Hungary

Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload

Phase 1

Completed

Conditions: β-thalassemia
Transfusional Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2007-11-20

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 11

Registration Number: NCT00560820

Locations: 🇮🇹
Novartis Investigative Site, Orbassano, Italy

Safety, Tolerability, and Efficacy of Deferasirox in MDS

Phase 3

Completed

Conditions: Hemosiderosis
Myelodysplastic Syndromes

Interventions: Drug: Deferasirox

First Posted Date: 2007-05-04

Last Posted Date: 2016-11-22

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 158

Registration Number: NCT00469560

Locations: 🇮🇹
SOC EMATOLOGIA ASO SS Antonio e Biagio, Alessandria, Italy
🇮🇹
Clinica Ematologica - Università degli Studi, Genova, Italy
🇮🇹
Clinica Ematol Università di Perugia, Policlinico Monteluce, Perugia, Italy

and more 14 locations

ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox

Completed

Conditions: Anemia

Interventions: Drug: Deferasirox

First Posted Date: 2007-04-27

Last Posted Date: 2015-12-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 108

Registration Number: NCT00466063

Locations: 🇺🇸
East Carolina University, Greenville, North Carolina, United States
🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸
Children's Hospital Oakland, Oakland, California, United States

and more 20 locations

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment

Phase 2

Completed

Conditions: Beta-thalassemia
Iron Overload

Interventions: Drug: Deferasirox

First Posted Date: 2007-03-15

Last Posted Date: 2021-06-14

Lead Sponsor: Novartis

Target Recruit Count: 30

Registration Number: NCT00447694

Locations: 🇺🇸
Children's Hospital and Research Center at Oakland, Oakland, California, United States
🇺🇸
Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Memorial Hospital, Chicago, Illinois, United States

Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Deferasirox

First Posted Date: 2007-02-08

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT00432627

Locations: 🇩🇪
Novartis Investigative Site, Kiel, Germany

Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2007-01-29

Last Posted Date: 2009-11-19

Lead Sponsor: Novartis

Target Recruit Count: 22

Registration Number: NCT00427505

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study

Phase 2

Completed

Conditions: Mucormycosis

Interventions: Drug: deferasirox
Drug: Placebo
Drug: Liposomal amphotericin B

First Posted Date: 2007-01-09

Last Posted Date: 2023-10-16

Lead Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Target Recruit Count: 20

Registration Number: NCT00419770

Locations: 🇺🇸
UCSF, San Francisco, California, United States
🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 4 locations

Effect of a Potent Inducer Rifampicin on the Pharmacokinetics of Deferasirox in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2007-01-08

Last Posted Date: 2009-11-19

Lead Sponsor: Novartis

Target Recruit Count: 22

Registration Number: NCT00419172

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Phase 2

Completed

Conditions: Transfusional Iron Overload
β-thalassemia Major
Pediatric Rare Anemia

Interventions: Drug: Deferasirox

First Posted Date: 2006-10-20

Last Posted Date: 2017-03-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT00390858

Locations: 🇮🇹
Novartis Investigative Site, Torino, Italy

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy